Resources
An epidemiological team investigates a hospital outbreak involving two cohorts. Cohort 1 () presents with acute bloody diarrhea caused by Shiga toxin-producing Escherichia coli (STEC). Cohort 2 () presents with acute viral gastroenteritis caused by Rotavirus. In Cohort 1, 60 patients are empirically treated with ciprofloxacin (a fluoroquinolone), while 60 receive supportive oral rehydration therapy (ORT). In Cohort 1, 15 out of 60 ciprofloxacin-treated patients develop Hemolytic Uremic Syndrome (HUS) due to SOS-response-mediated prophage toxin induction, compared to only 3 out of 60 in the ORT group. In Cohort 2, 70 receive nitazoxanide and 70 receive ORT alone, yielding resolution times of versus . (a) For Cohort 1, calculate the relative risk () of developing HUS following antibiotic administration. (b) For Cohort 2, calculate the percentage reduction in illness duration achieved by nitazoxanide compared to ORT alone. (c) Formulate the clinical guideline explaining why antimicrobial therapy is contraindicated in STEC infections, contrasting it with appropriate supportive care in viral gastroenteritis.
Answer and steps
Final answer
(a) ; . Relative risk . (b) Percentage reduction: . (c) Antibiotics such as fluoroquinolones induce a bacterial SOS response in STEC, triggering prophage induction and dramatically escalating Shiga toxin release, which increases the risk of renal microvascular thrombosis (HUS) fivefold. For both uncomplicated STEC and viral rotaviral gastroenteritis, the primary evidence-based standard of care is fluid and electrolyte rehydration therapy, avoiding unnecessary antimicrobial escalation.
Steps
Part (a): Relative Risk Calculation for Hemolytic Uremic Syndrome (HUS)
-
Calculate the incidence (risk) of HUS in each treatment group:
- In the ciprofloxacin-treated group (), patients developed HUS:
- In the oral rehydration therapy (ORT) group (), patients developed HUS:
-
Compute the Relative Risk ():
- The relative risk expresses how many times more likely the outcome occurs in the exposed group compared to the unexposed control group:
- Patients receiving ciprofloxacin had a -fold (or ) increased risk of progressing to HUS compared to those managed with supportive ORT.
Part (b): Percentage Reduction in Illness Duration for Viral Gastroenteritis
-
Identify baseline and intervention resolution times:
- Baseline duration with supportive care alone () =
- Duration with nitazoxanide intervention () =
-
Compute the absolute reduction and percentage decrease:
- Absolute time saved:
- Percentage reduction relative to the baseline duration:
Part (c): Clinical Guideline and Biological Mechanism
-
Mechanism of Harm in STEC:
- Shiga toxin genes (, ) are carried on lysogenic lambdoid prophages integrated within the E. coli genome.
- Antibiotics that interfere with bacterial DNA replication—especially fluoroquinolones like ciprofloxacin—induce significant DNA damage. This activates the bacterial SOS response (mediated by the RecA protein).
- The SOS response promotes the autocatalytic cleavage of the phage repressor, triggering the prophage into the lytic cycle. This leads to massive upregulation of Shiga toxin production, followed by cell lysis and systemic toxin release.
- Circulating Shiga toxin binds to receptors on renal glomerular endothelial cells, leading to microvascular thrombosis, hemolytic anemia, thrombocytopenia, and renal failure (HUS).
-
Clinical Contrast and Core Guideline:
- STEC Infections: Routine or empiric antimicrobial therapy is strictly contraindicated in suspected or confirmed STEC infections because it directly precipitates life-threatening HUS.
- Viral Gastroenteritis: Antibiotics provide no pharmacological benefit against viral pathogens such as Rotavirus. While targeted adjunctive therapies (e.g., nitazoxanide) can decrease illness duration, they are non-essential.
- Cornerstone of Therapy: For both STEC and acute viral enteritis, aggressive oral or intravenous fluid and electrolyte rehydration therapy (supportive care) is the proven, primary standard of care.
- Common Pitfall: Assuming acute, bloody diarrhea (dysentery) should automatically receive empiric broad-spectrum antibiotics before rapid diagnostic confirmation (such as stool PCR or Shiga toxin immunoassay). Initiating fluoroquinolones before ruling out STEC significantly endangers the patient.
Typical errors
01 The student calculates the odds ratio instead of the requested relative risk by comparing odds of HUS rather than probabilities.
Sample Student Work
Reviewed by ACEpath TeacherStep-by-Step Review
Walk Through It with Your Teacher- Step 1Correct
You calculated the odds ratio rather than relative risk. Relative risk compares the probability of the outcome occurring in each group (events divided by total cohort size, and ), whereas you divided events by non-events ( and ).
- Step 2
- Step 3
Antibiotics trigger the bacterial SOS response in STEC, inducing prophages that cause increased Shiga toxin production and cell lysis, raising HUS risk, so antibiotics are contraindicated. Viral gastroenteritis is unaffected by antibacterial agents, requiring supportive oral rehydration therapy.
WHAT YOU DID WELL
Compliments from Your TeacherYou accurately formulated the percentage reduction for the viral gastroenteritis cohort.
You clearly explained how antibiotic-induced SOS response and prophage activation increase the risk of hemolytic uremic syndrome in STEC.
THE ERROR
Where Your ACEpath Teacher Spotted the Mistakeno
WHY IT HAPPENED
ACEpath Teacher's DiagnosisYou treated risk (probability of an outcome relative to the total group) as odds (ratio of subjects with the outcome to subjects without the outcome), calculating an odds ratio instead of a relative risk.
REASONING PATH
Your ACEpath teacher’s suggested approach- Define Risk (Incidence Probability)
Always place the total group size in the denominator when calculating risk.
- Calculate Relative Risk
Divide the risk in the exposed group by the risk in the unexposed group rather than cross-multiplying discordant pairs.
CORRECTED PATH
ACEpath Teacher's DemonstrationFind the incidence risk in the ciprofloxacin group: .
Find the incidence risk in the supportive ORT group: .
Compute the relative risk: .
(a) ; (b) ; (c) Antibiotics induce the bacterial SOS response, triggering prophage induction and massive Shiga toxin release that increases HUS risk; fluid rehydration is the standard supportive care for both conditions.
02 The student uses the treated duration rather than the untreated baseline duration as the denominator when calculating the percentage reduction.
Sample Student Work
Reviewed by ACEpath TeacherStep-by-Step Review
Walk Through It with Your Teacher- Step 1
- Step 2
- Step 3Correct
You divided by the post-treatment duration () instead of the untreated baseline control duration (). Percentage reduction must always be calculated relative to the original baseline.
- Step 4
Fluoroquinolones trigger the SOS response in STEC, inducing prophages to increase Shiga toxin synthesis and release, drastically increasing HUS risk and making antibiotics contraindicated. Viral gastroenteritis does not respond to antibiotics, so supportive hydration is standard.
WHAT YOU DID WELL
Compliments from Your TeacherYou calculated both treatment group risks and the relative risk accurately.
You correctly found the absolute difference in hours between the two cohort groups.
You clearly articulated how fluoroquinolones induce the SOS response and escalate Shiga toxin production, making them contraindicated in STEC.
THE ERROR
Where Your ACEpath Teacher Spotted the MistakeNo, this is a conceptual confusion between the reference baseline and the final treated value when setting up relative percentage changes.
WHY IT HAPPENED
ACEpath Teacher's DiagnosisYou selected the new/treated duration () as the denominator rather than the untreated reference baseline (). Percentage change or reduction expresses how much smaller the value became relative to where it started.
REASONING PATH
Your ACEpath teacher’s suggested approach- Identifying the Baseline Denominator
Always identify the control or starting condition as the reference denominator before calculating percentage reduction.
CORRECTED PATH
ACEpath Teacher's DemonstrationIdentify the baseline untreated duration: .
Divide the absolute difference by the baseline: .
Convert to percentage: .
(a) ; (b) ; (c) Antibiotics induce the bacterial SOS response in STEC, triggering prophage lytic replication and massive Shiga toxin release, which increases HUS risk; fluid/electrolyte rehydration is the evidence-based standard of care.
03 The student attributes the contraindication of antibiotics in STEC purely to standard antibacterial resistance rather than SOS-mediated toxin upregulation.
Sample Student Work
Reviewed by ACEpath TeacherStep-by-Step Review
Walk Through It with Your Teacher- Step 1
- Step 2
- Step 3
Antimicrobials are contraindicated in STEC because widespread antibiotic use rapidly selects for resistant bacterial strains that render treatment ineffective, rather than benefiting the patient. Supportive oral rehydration is the mainstay in both STEC and viral diarrhea because antibiotics cannot treat viruses.
CorrectAntimicrobial therapy is contraindicated in STEC because DNA-damaging antibiotics (such as ciprofloxacin) trigger the bacterial SOS response, inducing lysogenic prophages to enter the lytic cycle. This causes massive upregulation and release of Shiga toxin, dramatically increasing the risk of microvascular endothelial injury and life-threatening Hemolytic Uremic Syndrome (HUS). Supportive fluid and electrolyte rehydration remains the evidence-based standard of care for both STEC and viral gastroenteritis.
While selecting for antibiotic resistance is a general epidemiological concern, it is not the reason antibiotics are strictly contraindicated in acute STEC. The direct clinical danger is that antibiotic-induced cellular stress triggers prophage induction and explosive Shiga toxin release, precipitating HUS.
WHAT YOU DID WELL
Compliments from Your TeacherYou accurately set up the proportions and calculated the relative risk of HUS as .
You correctly calculated the percentage reduction in resolution time for viral enteritis as .
You recognized that fluid rehydration is the cornerstone supportive therapy for acute gastroenteritis.
THE ERROR
Where Your ACEpath Teacher Spotted the Mistakeno
WHY IT HAPPENED
ACEpath Teacher's DiagnosisYou conflated a general public health concern (antimicrobial resistance selection) with the specific, acute pathophysiological mechanism of STEC-induced toxicity (SOS-response-mediated prophage induction and Shiga toxin release).
REASONING PATH
Your ACEpath teacher’s suggested approach- Evaluate Drug-Toxin Interactions
In bacterial infections harboring lysogenic prophage-encoded toxins (such as STEC genes), bactericidal antibiotics activate the RecA-dependent SOS response, leading to prophage excision, lytic replication, and massive toxin surge.
Always connect clinical contraindications to the specific molecular pathogen response rather than generic antimicrobial resistance.
- Connect Quantitative Findings to Guidelines
A fivefold increase in relative risk () points directly to severe acute drug toxicity/harm.
Use the calculated clinical outcome (HUS development) to explain why the drug directly harms the host.
CORRECTED PATH
ACEpath Teacher's DemonstrationIdentify the genetic location of Shiga toxin: Genes () reside within integrated lambdoid prophages in the E. coli genome.
Analyze the drug effect: Fluoroquinolones cause bacterial DNA breaks, triggering the RecA-mediated bacterial SOS response.
Trace the clinical cascade: Prophage induction leads to bacterial lysis, massive release of Shiga toxin into the bloodstream, binding to renal glomerular receptors, and initiation of Hemolytic Uremic Syndrome (HUS).
Synthesize guideline: Antibiotics are contraindicated because they directly induce life-threatening HUS, making supportive fluid management the safe, primary standard of care.
(a) ; (b) Percentage reduction ; (c) Antibiotics are contraindicated in STEC because DNA-damaging agents induce the bacterial SOS response, triggering prophage induction and a massive surge of Shiga toxin release, which precipitates life-threatening Hemolytic Uremic Syndrome (HUS).
Lock it in
What is the mathematical difference between Risk and Odds for a group of patients where patients experience an event?
(probability over the entire sample), whereas (ratio of events to non-events).
Similar question
In a clinical study of 80 patients hospitalized with bacterial pneumonia, 40 receive azithromycin and 40 receive standard amoxicillin. Clostridioides difficile colitis develops in 8 patients in the azithromycin group and 2 patients in the amoxicillin group. Calculate the relative risk (RR) of developing colitis associated with azithromycin.
Answer
; . Therefore, .
A clinic evaluates an antiviral for Influenza A. The duration of fever in the untreated supportive care group () is , while the duration in the antiviral-treated group () is . In addition, secondary bacterial pneumonia occurs in 4 treated patients versus 16 untreated patients. Calculate both the percentage reduction in fever duration and the relative risk of pneumonia in the treated cohort.
Answer
- Percentage reduction: .
- Relative risk: , . Thus, .
A cohort study investigates 200 pediatric patients with dysentery: 100 with Shigella sonnei and 100 with STEC. Both groups empirically receive trimethoprim-sulfamethoxazole (TMP-SMX). Among the Shigella cohort, 5 develop prolonged carriage and 95 resolve quickly. Among the STEC cohort, 20 develop HUS, whereas a historical control group of 100 STEC patients treated with supportive hydration alone had only 4 HUS cases. Calculate the relative risk of HUS from TMP-SMX exposure in STEC, and explain why empiric antibiotic selection must depend on rapid organism identification.
Answer
- .
- Empiric antibiotics eradicate invasive non-toxigenic pathogens like Shigella to shorten carriage, but in STEC they trigger prophage lytic activation, multiplying toxin production and markedly increasing HUS risk. Diagnostic identification is critical to avoid precipitating life-threatening toxicity.